Is REGENXBIO Inc. (RGNX) a Buy, Sell, or Hold?
REGENXBIO Inc.
NASDAQ:RGNX
$12.29 USD
-$0.46 (-3.61%)
- Volume
- 1.57M
- Average Volume
- 1.95M
- Market Capitalization
- $635.36M
- P/E Ratio
- -2.19
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $16.19
- Year Low
- $5.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.62
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Curran Simpson |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RGNX |
| CUSIP | 75901B107 |
| CIK | 0001590877 |
| Web | https://www.regenxbio.com |
| Phone | 240 552 8181 |
| Currency | USD |
| Employees | 371 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.37 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.62 |
| Quick Ratio | 2.62 |
| Cash Ratio | 0.21 |
Sales & Book Value
| Annual Sales | $170.44M |
| Price / Sales | 7.23 |
| Cash Flow | -4.51 |
| Price / Cash Flow | -2.69 |
| Price / Book | 30.56 |
Price Target and Rating
| Average Stock Price Forecast | $18.00 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -31.72% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 20 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.76 |
| Trailing P/E Ratio | -2.19 |
| PEG Ratio | 0.04 |
| P/E Growth | 0.04 |
| Net Income | $-193.88M |
| Net Margin | -330.23% |
| Pretax Margin | -330.23% |
| Return on Equity | -232.50% |
| Return on Assets | -84.83% |
Financials Score
| AltmanZ Score | -5.45 |
| Piotroski Score | 1.00 |
| Working Capital | 115.41M |
| Total Assets | 341.89M |
| Ebit | -244.87M |
| Market Cap | 659.14M |
| Total Liabilities | 320.81M |
Poll Results
About REGENXBIO Inc. (NASDAQ:RGNX) Stock
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for ... late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
2026-07-13 15:32:00
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders.
2026-06-29 07:05:00
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery.
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing
2026-06-28 08:45:00
REGENXBIO upgraded to 'Strong Buy' on FDA's course reversal for rare disease therapies, notably impacting NAVSUNLI [RGX-121] for MPS II. Company expects to resubmit NAVSUNLI BLA in Q3 2026, leveraging robust CAMPSIITE trial data and no new study requirements per FDA alignment. RGX-202 for DMD and sura-vec for wet AMD offer additional catalysts, with pivotal trial data and regulatory submissions anticipated through 2027.
2026-06-24 07:05:00
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting potential approval in 2H 2027 ROCKVILLE, Md., June 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy.
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
2026-06-23 11:51:08
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
2026-06-22 09:23:14
Regenxbio Inc. (NASDAQ:RGNX) on Monday said it aligned with the Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of Navsunli (RGX-121, clemidsogene lanparvovec).
2026-06-22 07:30:00
FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company expects to resubmit the BLA in Q3 2026 ROCKVILLE, Md., June 22, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121), the only potential one-time treatment and gene therapy for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome.
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
2026-06-22 07:01:40
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio , the Wall Street Journal reported on Monday.
Frequently Asked Questions
-
What is the current REGENXBIO Inc. (RGNX) stock price?
-
REGENXBIO Inc.(NASDAQ:RGNX) stock price is $12.29 in the last trading session. During the trading session, RGNX stock reached the peak price of $16.19 while $5.455 was the lowest point it dropped to. The percentage change in RGNX stock occurred in the recent session was --3.61% while the dollar amount for the price change in RGNX stock was -$-0.46.
-
RGNX's industry and sector of operation?
-
The NASDAQ listed RGNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RGNX?
-
Jahannaz Dastgir | Clinical Development Lead
Olivier Danos | Executive Vice President & Chief Scientific Officer
Ram Palanki | Executive Vice President & Chief Commercial Officer
Stephen Pakola | Executive Vice President & Chief Medical Officer
Craig Malzahn | Executive Vice President of Product Development & Chief Technology Officer -
How many employees does RGNX have?
-
Number of RGNX employees currently stands at 371. RGNX operates from 9804 Medical Center Drive, Rockville, MD 20850, US.
-
Link for RGNX official website?
-
Official Website of RGNX is: https://www.regenxbio.com
-
How do I contact RGNX?
-
RGNX could be contacted at phone #240 552 8181 and can also be accessed through its website. RGNX operates from 9804 Medical Center Drive, Rockville, MD 20850, US.
-
How many shares of RGNX are traded daily?
-
The average number of RGNX shares traded daily for last 3 months was 1.95M.
-
What is the market cap of RGNX currently?
-
The market value of RGNX currently stands at $635.36M with its latest stock price at $12.29